cetuxumab

Hummingbird and Merck to evaluate combination therapy for NSCLC
Clinical Trials Arena
Mon, 05/15/23 - 06:19 pm
Merck
Hummingbird Bioscience
HMBD-001
cetuxumab
squamous non-small cell lung cancer